…
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Swedish Orphan Biovitrum AB (publ) (Sobi) is a specialty biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases across hematology, immunology and other specialty care areas. Long-term growth may benefit from continued uptake of marketed products, an advancing clinical pipeline, partnerships and international expansion, which appears positioned to attract investors seeking exposure to niche, higher-margin specialty medicines.
Key risks include reliance on a limited number of revenue-generating products, regulatory and reimbursement uncertainty, competition from biosimilars or alternative therapies and execution risk in R&D and commercial expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 33.91M | 4407.00M | 2954.00M | 3321.00M | 3295.00M |
| Minority interest | 2.00M | 6.00M | 0.00M | - | - |
| Net income | 476.80M | 3885.00M | 2409.00M | 2638.00M | 2679.00M |
| Selling general administrative | 11144.00M | 7553.00M | 10161.00M | 7847.00M | 6294.00M |
| Selling and marketing expenses | - | 3532.00M | 3483.00M | - | - |
| Gross profit | 12289.09M | 20242.00M | 17128.00M | 14014.00M | 12045.00M |
| Reconciled depreciation | 10096.00M | 3679.00M | 2827.00M | 2419.00M | 2006.00M |
| Ebit | 864.83M | 5625.00M | 4065.00M | 3813.00M | 3733.00M |
| Ebitda | 10935.50M | 9304.00M | 7234.00M | 6198.00M | 5776.00M |
| Depreciation and amortization | 10070.67M | 3679.00M | 3169.00M | 2385.00M | 2043.00M |
| Operating income | 8027.81M | 5625.00M | 4066.00M | 3813.00M | 3733.00M |
| Other operating expenses | 20139.35M | 20402.00M | 18057.00M | 14945.00M | 11742.00M |
| Interest expense | 828.92M | 1239.00M | 1111.00M | 458.00M | 419.00M |
| Tax provision | -442.00M | 528.00M | 714.00M | 683.00M | 616.00M |
| Interest income | 22.00M | 32.00M | 27.00M | 5.00M | 0.00M |
| Net interest income | -831.00M | -1219.00M | -878.00M | -481.00M | -454.00M |
| Income tax expense | -440.89M | 528.00M | 546.00M | 683.00M | 616.00M |
| Total revenue | 28167.16M | 26027.00M | 22123.00M | 18790.00M | 15529.00M |
| Total operating expenses | 4261.28M | 14617.00M | 13062.00M | 10169.00M | 8258.00M |
| Cost of revenue | 15878.07M | 5785.00M | 4995.00M | 4776.00M | 3484.00M |
| Total other income expense net | -7993.90M | -1218.00M | -1112.00M | -492.00M | -438.00M |
| Net income from continuing ops | 476.00M | 3879.00M | 2769.00M | 2638.00M | 2679.00M |
| Net income applicable to common shares | - | - | - | 2638.00M | 2679.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 67264.84M | 75444.00M | 74027.00M | 52496.00M | 48661.00M |
| Intangible assets | 39955.52M | 48515.00M | 49341.00M | 33006.00M | 32135.00M |
| Other current assets | -0.00M | 1.00M | 7893.00M | 123.00M | 1.00M |
| Total liab | 29636.47M | 35149.00M | 40160.00M | 25971.00M | 25458.00M |
| Total stockholder equity | 37622.39M | 40286.00M | 33867.00M | 26525.00M | 23203.00M |
| Deferred long term liab | - | - | - | - | 517.00M |
| Other current liab | 8755.98M | 7596.00M | 9036.00M | 7676.00M | 1041.00M |
| Common stock | 195.51M | 195.00M | 194.00M | 170.00M | 169.00M |
| Capital stock | 196.00M | 195.00M | 194.00M | 170.00M | 169.00M |
| Retained earnings | 22345.80M | 21924.00M | 18055.00M | 15793.00M | 13155.00M |
| Other liab | - | - | - | 7943.00M | 7673.00M |
| Good will | 9001.36M | 10456.00M | 9642.00M | 7007.00M | 6288.00M |
| Other assets | - | - | - | 1.00M | 1338.00M |
| Cash | 1038.39M | 1140.00M | 904.00M | 1361.00M | 1045.00M |
| Total current liabilities | 16028.69M | 12600.00M | 19095.00M | 14857.00M | 8761.00M |
| Current deferred revenue | - | - | 2904.00M | - | 5280.00M |
| Net debt | 10686.13M | 15595.00M | 19581.00M | 7739.00M | 9861.00M |
| Short term debt | 6040.81M | 4060.00M | 8961.00M | 5929.00M | 1882.00M |
| Short long term debt | 5942.00M | 3926.00M | 8813.00M | 5795.00M | 1768.00M |
| Short long term debt total | 11724.51M | 16735.00M | 20485.00M | 9100.00M | 10906.00M |
| Other stockholder equity | 15081.07M | 18167.00M | 15618.00M | 10562.00M | 9879.00M |
| Property plant equipment | - | - | - | 274.00M | 493.00M |
| Total current assets | 14491.56M | 13162.00M | 12671.00M | 11210.00M | 8778.00M |
| Net tangible assets | - | - | - | -13488.00M | -14704.00M |
| Short term investments | - | - | 105.00M | - | -9.00M |
| Net receivables | 8339.03M | 7862.00M | 7062.00M | 5248.00M | 4308.00M |
| Long term debt | 5180.00M | 12407.00M | 11356.00M | 2971.00M | 8777.00M |
| Inventory | 5114.14M | 4159.00M | 3874.00M | 3332.00M | 3424.00M |
| Accounts payable | 1231.90M | 944.00M | 1024.00M | 1252.00M | 558.00M |
| Accumulated other comprehensive income | - | - | -934.00M | - | - |
| Non currrent assets other | 211.47M | 398.00M | 2085.00M | 121.00M | 1.00M |
| Non current assets total | 52773.28M | 62282.00M | 61356.00M | 41285.00M | 39883.00M |
| Capital lease obligations | 373.00M | 402.00M | 316.00M | 334.00M | 361.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -41.00M | -3091.00M | -21509.00M | -1477.00M | -367.00M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | -4283.23M | -3091.00M | -21904.00M | -1477.00M | -367.00M |
| Net borrowings | -4933.00M | -4436.00M | 11248.00M | -2553.00M | -4123.00M |
| Total cash from financing activities | -4312.16M | -4001.00M | 17012.00M | -2991.00M | -4474.00M |
| Change to operating activities | - | - | - | -807.00M | 980.00M |
| Net income | 476.80M | 4407.00M | 2954.00M | 3321.00M | 3295.00M |
| Change in cash | 92.52M | 236.00M | -457.00M | 316.00M | 641.00M |
| Begin period cash flow | 945.87M | 904.00M | 1361.00M | 1045.00M | 404.00M |
| End period cash flow | 1038.39M | 1140.00M | 904.00M | 1361.00M | 1045.00M |
| Total cash from operating activities | 8542.52M | 7388.00M | 4470.00M | 4665.00M | 5470.00M |
| Issuance of capital stock | 245.00M | 427.00M | 6129.00M | - | - |
| Depreciation | 10070.67M | 3679.00M | 3200.00M | 2419.00M | 2006.00M |
| Other cashflows from investing activities | -95.76M | -2921.00M | -4536.00M | - | - |
| Change to inventory | -1077.00M | -159.00M | 286.00M | 413.00M | -318.00M |
| Change to account receivables | - | -178.00M | -901.00M | -1982.00M | 452.00M |
| Other cashflows from financing activities | 364.08M | 8.00M | -365.00M | 13103.00M | 13717.00M |
| Change to netincome | - | - | - | 556.00M | -322.00M |
| Capital expenditures | 39.90M | 3005.00M | 4943.00M | 1477.00M | 370.00M |
| Change in working capital | -506.73M | -179.00M | -1160.00M | -806.00M | 1114.00M |
| Stock based compensation | 250.00M | 218.00M | 298.00M | - | - |
| Other non cash items | -1498.23M | -519.00M | -524.00M | -269.00M | -945.00M |
| Free cash flow | 8502.62M | 4383.00M | -473.00M | 3188.00M | 5100.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIOVF Swedish Orphan Biovitrum AB (publ) |
- -% |
51.05 | 275.47 | 23.09 | 4.50 | 3.35 | 5.49 | 14.18 |
| MKKGY Merck KGaA ADR |
-0.34 1.04% |
32.49 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.10 1.27% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.15 0.71% |
21.42 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Dr. Guido Oelkers | CEO & Pres | 1965 |
| Dr. Anders Ullman M.D., Ph.D. | Head of R&D & Medical Affairs and Chief Medical Officer | 1956 |
| Mr. Henrik Stenqvist | Chief Financial Officer | 1968 |
| Ms. Christine Wesstrom | Head of Technical Operations | 1975 |
| Mr. Thomas Kudsk Larsen | Head of Communication & Investor Relations | 1974 |
| Mr. Torbjörn Hallberg | Gen. Counsel and Head of Legal Affairs & HR | 1969 |
| Mr. Daniel Rankin | Head of Strategy & Corp. Devel. | 1980 |
| Pablo de Mora | Head of Global Marketing & Access | 1968 |
| Mr. Philip Wood | Head of Haematology | 1968 |
| Ms. Konstantina Karampela | Sr. Director of European Commercial Operations (Specialty Care and Partner Products) | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.